Successful treatment of hepatitis C genotype 4 using sofosbuvir, daclatasvir, simeprevir and ribavirin in Egyptian patients with direct-acting antiviral agent treatment failure

INTRODUCTION: In chronic hepatitis C virus (HCV) patients in whom prior direct-acting antiviral agent (DAA) treatment had failed, outcomes after retreatment are optimal. Combination of sofosbuvir (SOF), daclatasvir (DCV), simeprevir (SIM), and ribavirin (RBV) in treatment experienced patients is rec...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohamed, Hala, Ghany, Weal Abd El, Yehia, Reem, Fouad, Magdy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984792/
https://www.ncbi.nlm.nih.gov/pubmed/35415259
http://dx.doi.org/10.5114/ceh.2022.114246

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8984792/
https://www.ncbi.nlm.nih.gov/pubmed/35415259
http://dx.doi.org/10.5114/ceh.2022.114246

Ejemplares similares